AGO Breast Study Group
@AgoStudy
Followers
161
Following
130
Media
17
Statuses
101
MonarchE reported an overall survival benefit of abemaciclib in high risk early breast cancer. https://t.co/QF39JlUigy Likely we see that data at this years ESMO in Berlin https://t.co/CHKKUKKSZ5 Good chance we also see an update of NATALEE. Great that these studies mature.
6
0
1
Mal eine andere Art der Publikation: Mammografie-Screening senkt Mortalität wahrscheinlich um 20 bis 30% (bei allen Schwierigkeiten solcher Auswertungen). Toller Erfolg für die Prävention. Prävention muss weiter besser werden!!! https://t.co/ClP0bOS4jG
https://t.co/JQ9sxY4E0R
0
0
2
Now Destiny-B06 Study with a positive CHMP opinion https://t.co/x25ZcdGzhH Then T-Dxd will possible in ultralow HER2 expressing tumors and without previous chemotherapy. Good to have more therapeutic options for new therapy sequences. #breastcancer #tdxd #ultralow
0
0
1
Serena-6 study seems to be positive - another milestone in individualized healthcare for patients with advanced breast cancer https://t.co/NJJdkkSyHL Hopefully we see this data at ASCO2025 #breastcancer #serd #asco2025
astrazeneca.com
0
0
2
Neoadjvuant Radiotherapy: new insights with important information that might be useful current clinical trial design https://t.co/9LEUvqmGWE
#breastcancer #radiotherapy
0
0
1
Great month for Datopotamab-deruxtecan for HRpos/HER2neg aBC patients: After Approval in the US two weeks ago: https://t.co/qJT65Q2jhq Also Approval recommendation by the EMA yesterday https://t.co/HuPpKnebvV
ema.europa.eu
0
0
0
INAVO120 Study seems to be positive for overall survival. Excellent news for patients !!! https://t.co/W1t7T9urwY Assuming data will be presented at ASCO in 4 months we have to wait for this data quite some time. Maybe find a way to immendiately share the data, when anndouncing?
roche.com
Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positi...
0
0
0
Good for the therapy landscape: T-Dxd approved in the U.S. in the DB-06 Population (Patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies). https://t.co/GKLA9xYCsP
https://t.co/EPXfX2mR6S
nejm.org
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with me...
0
0
1
Gipfelstürmer Neuauflage 2025 in der "wahren Hauptstadt Deutschlands" (Zitat eines berühmten Gynäkologen): https://t.co/utP9h3uOeC
0
0
0
Nächste Woche geht es wieder los! Der #SABCS24 öffnet seine Türen! #onkowissenTV ist natürlich wieder live vor Ort und berichtet von den neuesten Daten! Ganz neu dieses Jahr: der onkowissenTV Livestream mit allen wichtigen Updates des Jahres 2024 im Bereich #Mammakarzinom. Jetzt
0
2
3
Kisqali - opinion on variation to marketing authorisation | EMA https://t.co/AgIo1zFth4 After the U.S., now positive opinion on early breast cancer ribociclib use a consequence of positive outcome data of NATALEE https://t.co/1g5HJN1S2e
#breastcancer #ribociclib #natalee
1
1
2
Keynote-522 every third breast cancer death prevented. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine
nejm.org
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition...
0
0
2
Yesterday 4yr survival update of NATALEE: https://t.co/kwZpnfEL74 Today FDA Approval for Ribociclib in the adjuvant setting: https://t.co/R5YOzTjtMZ
#breastcancer
0
0
1
Gestern 4yr survival update von NATALEE: https://t.co/kwZpnfEL74 Heute in den USA die Zulassung für high risk HRpos/HER2neg eBC: https://t.co/R5YOzTjtMZ
#brustkrebs #breastcancer
0
0
1
Breast Cancer Screening Interval: Screening Ergebnisse anders herum. Screening scheint auch bei jungen Frauen das Stadium günstig zu beeinflussen. Zeit, auch das Vorgehen in Deutschland neu zu disktuieren?
ascopubs.org
PURPOSEControversy continues regarding the effect of screening mammography on breast cancer outcomes. We evaluated late-stage cancer rate and overall survival (OS) for different screening intervals...
0
0
1
Die finalen Mammografie-Screening-Empfehlungen, die das Eintritts-Alter in den USA auf 40 senken, sind verabschiedet https://t.co/RRRQk9tQzx Zeit, sich auch in Deutschland die Epidemiologie und das Erkrankungsalter noch einmal anzuschauen? #mammakarzinom #screening #mammografie
0
0
1
Jetzt anmelden: AGO Mammakarzinom State of the Art 2024 – alle neuen Therapie-Empfehlungen der Kommission Mamma live in Frankfurt am 02.03.2024. Auch virtuelle Teilnahme möglich. https://t.co/w6HM8aCpIY
0
6
7
New analysis in HRPos/HER2neg BC patients shows the prognosis of the groups according to inclusion/exclusion criteria of MonarchE and NATALEE in a German Cohort study of letrozole treated HRpos/HER2neg patients.
0
0
2
Virtuell und vor Ort: neue Therapie-Empfehlungen für Patientinnen mit Mammakarzinom und für Früherkennung/Diagnostik #mammakarzinom #brustkrebs #therapie #diagnostik
https://t.co/w6HM8aCXyw
0
2
7
The German RIBECCA Study was a phase IIIB study short after the publication of Monaleesa-2. With 21.8 months median PFS is very similar compared to the randomized clinical trials. Large translational research program to follow. https://t.co/C2HV385dtA
0
1
1